The post Bitcoin News: Bitcoin Slide Below $75K Pushes Saylor’s Strategy Into $900M Unrealized Loss appeared on BitcoinEthereumNews.com. Bitcoin falling below $The post Bitcoin News: Bitcoin Slide Below $75K Pushes Saylor’s Strategy Into $900M Unrealized Loss appeared on BitcoinEthereumNews.com. Bitcoin falling below $

Bitcoin News: Bitcoin Slide Below $75K Pushes Saylor’s Strategy Into $900M Unrealized Loss

Bitcoin falling below $75,000 creates major unrealized losses for Strategy and BitMine, raising balance sheet stress and liquidation concerns globally.

Bitcoin fell below $75,000, triggering sharp unrealized losses across several high-profile corporate crypto holders. Consequently, market volatility was on the rise, and the focus of investors was moving towards balance sheet resiliency and treasury risk.

Strategy’s Bitcoin Treasury Turns Underwater as Prices Weaken

According to Lookonchain’s January 2026 disclosures, Strategy has 712,647 BTC on its corporate balance sheet. Notably, the overall acquisition cost is close to $54.19 billion, a result of years of aggressive acquisitions.

However, Strategy’s average cost basis is $76,037 per BTC, so that holdings are now technically underwater. As Bitcoin moved between $74,700 and $75,300 on February 2, unrealized losses were over $900 million.

Related Reading: Tom Lee’s BitMine Suffers $6.9B Ethereum Loss

Importantly, Strategy’s Bitcoin is still not resilient and is not pledged as collateral. Therefore, there is no immediate forced selling risk in spite of the ongoing price volatility and stress in the market.

Meanwhile, Strategy kept buying more Bitcoin throughout January 2026 despite renewed volatility and uncertainty. Specifically, the company bought 1,287 BTC in early January and another 2,932 BTC later.

Additionally, Strategy has financial flexibility with ~$2.25 billion USD cash reserves. These reserves are used to support interest obligations on $8.2 billion in convertible debt.

Furthermore, observers point out that Strategy’s long-term approach places an emphasis on holding, rather than reacting to short-term swings. As a result, paper losses still stand as accounting figures that have no direct impact on the operational liquidity.

Nevertheless, plummeting prices have caused the corporate crypto treasury and risk management practices to come under heightened scrutiny. Consequently, investors focus more on liquidation exposure, leverage structures, and treasury transparency disclosures.

Ethereum Slump Deepens Pressure on Tom Lee’s BitMine

This wider caution came as Ethereum’s weakness put pressure on parallel companies that were exposed to crypto. BitMine reported an unrealized Ethereum loss of almost $6.9 billion as ETH traded near $2,300. Therefore, the drop in valuation led to a greater level of stress on the balance sheet and put pressure on company stocks.

The firm has a large position of Ethereum, which was taken up while the market was higher. Consequently, extended ETH weakness could have a material impact on the stability of equity and investor confidence worldwide.

Unlike Strategy, BitMine’s exposure looks more concentrated in order to be sensitive to Ethereum’s price movements. As a result, analysts caution that sustained declines could cause even greater financing and liquidity problems.

However, neither company has announced forced asset sales despite mounting unfulfilled losses. Nevertheless, ongoing market weakness may play into the future capital allocation and treasury strategies.

Looking ahead, Michael Saylor is bullish about long term adoption trajectory of Bitcoin as publicised in the following lines: Previously, he predicted Bitcoin finding $150,000 for the cycle of 2025 or 2026.

At the same time, investors are becoming increasingly sensitive to the risk of liquidation as prices test corporate balance sheet tolerance. Therefore, transparency, reserve buffers, and leverage discipline are still very important under volatile conditions.

Source: https://www.livebitcoinnews.com/bitcoin-slide-below-75k-pushes-saylors-strategy-into-900m-unrealized-loss/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26